Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
Clinical characteristics and glycemic outcomes of patients with Type 2 diabetes who need a maximum amount of Insulin Glargine/Lixisenatide fixed-rate combination or Insulin Glargine in the LixiLan-L trial.